{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-199907","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2023-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.609459+00:00","generated_at":"2026-06-12T18:23:02.383705+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Revolution Medicines to acquire EQRx in stock deal valued at ~$1.07B; pipeline updates and FY2023 guidance","bullets":["Merger consideration: $200M fixed (7.69M shares) plus $870M based on pre-meeting VWAP with 6% discount; expected close Nov 2023.","Voting agreements secured with >40% of EQRx shares and ~8% of RVMD shares to support the transaction.","Company confirms FY2023 GAAP net loss guidance of $360M-$400M, inclusive of $40M-$50M stock-based compensation.","Pipeline updates: RMC-6236 clinical data in NSCLC/pancreatic cancer expected Oct 2023; planning pivotal trials for 2024.","Post-merger, company will not advance EQRx pipeline; EQRx programs to be wound down and IP returned to partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-199907","json":"https://secwatch.observer/filing/0001193125-23-199907.json","markdown":"https://secwatch.observer/filing/0001193125-23-199907.md","text":"https://secwatch.observer/filing/0001193125-23-199907.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/0001193125-23-199907-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/d534121d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T18:23:02.383705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"095a86ae96aaed41daa68a27c1933559f190ab22","claim":"Revolution Medicines, Inc. entered into Agreement and Plan of Merger with EQRx, Inc. (effective 2023-07-31).","evidence_excerpt":"On July 31, 2023, Revolution Medicines, Inc., a Delaware corporation (the “Company”), EQRx, Inc., a Delaware corporation (“EQRx”), Equinox Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of the Company (“Merger Sub I”), and Equinox Merger Sub II LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of the Company (“Merger Sub II”), entered into an Agreement and Plan of Merger (the “Merger Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000119312523199907/0001193125-23-199907-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"EQRx, Inc."},{"label":"Effective","value":"2023-07-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}